Kalaris Therapeutics, Inc. (KLRS)
4.01
-0.09
(-2.20%)
USD |
NASDAQ |
Aug 28, 16:00
4.01
0.00 (0.00%)
After-Hours: 20:00
Kalaris Therapeutics Cash from Operations (Quarterly) : -11.43M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.43M |
| March 31, 2026 | -13.35M |
| December 31, 2025 | -9.317M |
| September 30, 2025 | -11.33M |
| June 30, 2025 | -14.88M |
| March 31, 2025 | -7.441M |
| December 31, 2024 | -10.25M |
| September 30, 2024 | -4.327M |
| June 30, 2024 | -3.993M |
| March 31, 2024 | -4.521M |
| December 31, 2023 | -30.74M |
| September 30, 2023 | -34.48M |
| June 30, 2023 | -27.12M |
| March 31, 2023 | -32.12M |
| December 31, 2022 | -31.57M |
| Date | Value |
|---|---|
| September 30, 2022 | -35.13M |
| June 30, 2022 | -28.88M |
| March 31, 2022 | -46.48M |
| December 31, 2021 | -28.07M |
| September 30, 2021 | -36.44M |
| June 30, 2021 | -22.89M |
| March 31, 2021 | -18.93M |
| December 31, 2020 | -21.09M |
| September 30, 2020 | -18.06M |
| June 30, 2020 | -11.12M |
| March 31, 2020 | -10.54M |
| December 31, 2019 | -8.868M |
| September 30, 2019 | -6.403M |
| June 30, 2019 | -2.907M |
| March 31, 2019 | -1.977M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Replimune Group, Inc. | -75.73M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
| Sarepta Therapeutics, Inc. | 197.07M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 20.17M |
| Cash from Financing (Quarterly) | 0.01M |
| Free Cash Flow | -45.63M |
| Free Cash Flow Per Share (Quarterly) | -0.4804 |
| Free Cash Flow to Equity (Quarterly) | -11.42M |
| Free Cash Flow to Firm (Quarterly) | -11.43M |
| Free Cash Flow Yield | -51.07% |